At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I and II Study of Stereotactic Body Radiation Therapy (SBRT) for Low and Intermediate Risk Prostate Cancer (SBRT Prostate)
In Brief
A Phase 2 clinical trial evaluating stereotactic body radiation therapy (SBRT)- 45 Gy, stereotactic body radiation therapy (SBRT) - 47.5 Gy, and 2 other interventions for Prostate Cancer. Completed, enrolled 94 participants across 5 sites.
Detailed Summary
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I/II trial is studying the side effects and best dose of stereotactic body radiation therapy and to see how well it works in treating patients with prostate cancer.
Study Details
Timeline
Interventions
Dose of SBRT - 45 Gray (Gy) in five fractions
Dose of SBRT - 47.5 Gray (Gy) in five fractions